Skip to main content
main-content

27.04.2019 | PRECLINICAL STUDIES

Anticancer activity, apoptosis and a structure–activity analysis of a series of 1,4-naphthoquinone-2,3-bis-sulfides

Zeitschrift:
Investigational New Drugs
Autoren:
Kevin W. Wellington, Natasha I. Kolesnikova, Vincent Hlatshwayo, Sourav T. Saha, Mandeep Kaur, Lesetja R. Motadi
Wichtige Hinweise

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

We have previously reported on the synthesis of 1,4-naphthoquinone-sulfides and in this investigation we report on their anticancer activity against 6 human cancer cell lines to evaluate their cytostatic effects. The 1,4-naphthoquinone-2,3-bis-sulfides were most effective against melanoma (UACC62) (GI50 = 6.5–10 μM) and prostate (PC3) (GI50 = 5.51–8.53 μM) cancer cell lines. They exhibited better cytostatic effects than etoposide (GI50 = 0.56–36.62 μM), parthenolide (GI50 = 3.58–25.97 μM) and VK3 (GI50 = 3.41–22.59 μM) against several of the cancer cell lines. These compounds are generally more selective for cancer cells than for normal human lung fetal fibroblasts (WI-38). One compound produces ROS which results in breast (MCF7) cancer cell death caused by apoptosis as evidenced by caspase 3/7 activation. Apoptosis was found to occur by a mitochondrial pathway and not by cell cycle arrest. Gene expression studies showed that p53 (a tumour suppressor), Mdm-2 (a p53 regulator) and Bcl-2 (apoptosis inhibitor) were up-regulated during apoptosis induction. These results encourage further research for potential application in cancer chemotherapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Literatur
Über diesen Artikel

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise